A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"

Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1.
No abstract available

Keywords: COPD; Fixed-effects model; Fluticasone furoate/umeclidinium/vilanterol; Heterogeneity; Indirect treatment comparison; Network meta-analysis; Random effects model; Triple therapy.

Publication types

  • Meta-Analysis
  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Administration, Inhalation
  • Androstadienes* / therapeutic use
  • Benzyl Alcohols / therapeutic use
  • Bronchodilator Agents / therapeutic use
  • Chlorobenzenes / therapeutic use
  • Drug Combinations
  • Fluticasone / therapeutic use
  • Humans
  • Network Meta-Analysis
  • Pulmonary Disease, Chronic Obstructive* / drug therapy
  • Quinuclidines / therapeutic use

Substances

  • fluticasone furoate
  • GSK573719
  • vilanterol
  • Fluticasone
  • Androstadienes
  • Benzyl Alcohols
  • Chlorobenzenes
  • Quinuclidines
  • Bronchodilator Agents
  • Drug Combinations